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Abstract Brucellosis is a zoonosis disease of worldwide importance among animal and humans. Themost
important virulence factor of Brucella spp. is related to its intramachrophage survival. On the other hand,
because of the side effects of the current brucellosis treatment regime, it is necessary to find out new
antimicrobial agents to treat the disease. The aim of this study is to investigate the antibacterial effect
of silver nanoparticles against Brucella under an intramacrophage condition. A well diffusion agar test
showed the activity of silver nanoparticles against Brucella melitensis 16M. Macrodilution experiments
demonstrated the MIC and MBC of silver nanoparticles 4 and 6 ppm, respectively. The incubation time
study showed that silver nanoparticles were able to kill bacteria within 40 min after the reaction.
The cell culture study revealed that silver nanoparticles have effective antimicrobial activity inside the
macrophage cells in concentrations of 4–6 ppm and the findings showed that one may consider silver
nanoparticles as a new nano drug against intramachrophage Brucella melitensis 16M.
© 2013 Sharif University of Technology. Production and hosting by Elsevier B.V.
Open access under CC BY license. 1. Introduction
Brucellosis is a zoonosis disease with well described man-
ifestations and complications which is most frequent in the
Mediterranean basin and South America [1]. Brucellosis is a
systemic infection in which the bacteria initially localize in
the regional lymph nodes and then disseminate hamatoge-
nously to the organs of the reticuloendothelial system to mul-
tiply with in phagocyte cells [2]. Brucella spp. are short, non-
motile, nonsporulating, nonencapsulated and Gram-negative
aerobic rod bacteria that are important facultative intracellu-
lar pathogens of humans and livestock. Brucella melitensis usu-
ally infects sheep, goats and camels and is the most pathogenic
species for humans [3]. After entrancing the bacteria to a host,
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doi:10.1016/j.scient.2013.02.018they are taken up by macrophages and display a remarkable
resistance to be killed by phagocytosis [4,5]. Macrophages are
particularly important for survival and spread of Brucella dur-
ing infection [6]. Drug resistance, multidrug therapy and re-
lapsing cases are the most important problems caused by using
chemical antimicrobial agents [7,8] and therefore, an alterna-
tiveway to overcome these problems is needed. Silver nanopar-
ticles have large surface areas in comparison with bulk metals.
Ag ions and Ag salts have been used for decades as antimicro-
bial agents in various fields because of their growth-inhibitory
capacity against microorganisms and many investigators are
interested in using silver nanoparticles as antibacterial agents
[9–11]. Different studies have established the bactericidal ef-
fect of nanosilver in Gram negative and Gram positive bac-
teria. Morones et al. defined the antibacterial activity of silver
nanoparticles in 4 types of Gram negative bacteria: Escherichia
coli, Vibrio cholera, Pseudomonas aeruginosa and Salmonella
typhi. They suggested that silver nanoparticles attach to the
surface of the cell membrane of bacterium and disturb its func-
tion [12]. Other researchers determined a similar antibacte-
rial activity in Gram positive bacteria such as Bacillus subtilis,
S. aureus, and Enterococcus faecalis [13]. However, the antimi-
crobial effect of silver nanoparticles against Brucella and intra-
macrophage Brucella has not been yet studied.
evier B.V. Open access under CC BY license. 
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2.1. Materials and media
Brucellamelitensis 16Mwas obtained from thedepartment of
bacterial vaccine and antigenproduction of the Pasteur institute
of Iran. This strain is virulent for humans and animals. Silver
nanoparticles were purchased from Nanocide company in the
size range of 3–18 nm and concentration of 4000 ppm. All the
microbial media were obtained from Merck, Germany.
2.2. Antimicrobial activity
Muller–Hinton agar was supplemented with 1% sheep’s
blood. 5mmdiameterwellswere prepared and1.5×108 cfu/ml
of B. melitensis 16M suspension was cultivated in plates with
a sterile swab and then, the wells were loaded with silver
nanoparticle dilutions (70 µl of 2, 5, 10, 20, 50, 100, 250,
500, 1000 and 2000 ppm). The plates were incubated at 37 °C
under 7%–10% CO2 for 72 h. The zone of growth inhibition was
measured by a ruler [14].
2.3. MIC and MBC
Serial dilutions of silver nanoparticles (1, 2, 5, 10, 20,
50, 100, 250, 500, 1000 and 2000 ppm) were prepared in a
Muller–Hinton broth supplemented with 1% sheep’s blood in
tubes. Then, 5 × 105cfu/ml of B. melitensis 16M suspension
was added to each tube and incubated at 37 °C under
7%–10% CO2 for 72 h. Next, the tubes were examined for
turbidity. The lowest concentration of silver nanoparticles to
inhibit the growth of B. melitensis 16M was designated as
the minimum inhibitory concentration (MIC). For calculation
of the minimum bactericidal concentration (MBC) of silver
nanoparticles, 0.1 ml of inoculums from each tube was sub-
cultured on Muller–Hinton agar plates supplemented with 1%
sheep’s blood [15]. The number of colonies on the agar after
72 h of incubation under the same conditions was counted and
compared with the number of cfu/ml in the original inoculums.
The lowest concentration of silver nanoparticles that can kill the
bacteria is determined as MBC.
2.4. Effect of incubation time
TheMBC concentration of silver nanoparticles was prepared
in a Muller-Hinton broth supplemented with 1% sheep’s
blood in a tube. Then, 5 × 105 cfu/ml of B. melitensis 16M
suspension was added to the tube and incubated at 37 °C
under 7%–10% CO2. At time intervals (0, 20, 40 min, 1, 2, 4,
6 and 24 h after culturing), 0.1 ml of inoculums was sub-
cultured on Muller–Hinton agar plates supplemented with
1% sheep’s blood. The growth or no growth of B. melitensis
16M was investigated at different time intervals after 72 h of
incubation [15].
2.5. Preparation of peritoneal macrophages
Thioglycollat-elicited peritoneal exudates cells were pre-
pared from 6 to 8 weeks old female BALB/c mice. Firstly, 1 ml
of thioglycollate broth (4.05 g/100 ml) was injected intraperi-
toneally. Then, the lavage of the peritoneal cavity was filled by
5ml ofmedium (RPMI 1640 enrichedwith 10% heat-inactivated
fetal calf serum (FCS) plus 5 unit injection Heparine) 4 days
later. The cells were washed twice and resuspended in RPMI1640 with 10% FCS. Next, 0.27 × 104 macrophage cells were
placed in each well of a 96 well polystyrene micro titer plate.
The plates were incubated for 2 h at 37 °C with 5% CO2, allowed
adhering. Then, the supernatant was aspirated and the mono-
layer adherent was washed three times with the medium [15].
2.6. Treatment of macrophages with silver nanoparticles
To determine the effect of silver nanoparticles on the
viability of macrophages, murine peritoneal macrophages were
incubated with the silver nanoparticles for 24 h. Peritoneal
exudate cells were counted for finding viability using a dye
exclusion test with trypan blue before and after 24 h of
incubation of themacrophages with different dilutions of silver
nanoparticles (12, 10, 8, 6, 4 and 2ppm). Normal salinewas used
as negative control [15].
2.7. Effect of silver nanoparticles on intramacrophage Brucella
melitensis 16M
In order to assess the number of colony forming units
(CFU) of Brucella melitensis 16M in macrophage lysate for
treated and untreated macrophages, the lysates were cultured
on Brucella agar. B. melitensis 16M was grown at 37 °C in
Brucella agar under 7%–10% CO2 for 48 h, resuspended in
phosphate-buffer saline (PBSI), washed and resuspended in the
same buffer. Then, bacterial suspension (5 × 105 cfu/ml) was
added to the peritoneal macrophages and incubated for 2 h
under the same conditions as mentioned above, allowing the
macrophages to ingest the Brucella melitensis16M [16]. Then,
antibiotic gentamicin at a concentration of 50µg/mlwas added
to the wells and the microplates were incubated for 1 h to
kill extracellular bacteria. Then, the monolayer was washed
three times with the medium and different dilutions of silver
nanoparticles (1, 2, 4, 8 and 10 ppm) were added to the wells.
After 24 h of incubation, Triton X-100 was used to lysis the
macrophages. Then, the number of CFU in the lysates was
determined by serial dilutions and plated on Brucella agar.
Normal saline was used as negative control [15].
2.8. Statistical analysis
The results were analysed by one way ANOVA test by SPSS
18 software. The P-value in this study was less than 0.05.
3. Results and discussion
Brucella bacteria are relatively sensitive to a wide range of
antibiotics and antibacterial agents, but in single drug regimen,
relapses are common. Brucella spp. are facultative intracellular
bacteria that can survive within the phagocyte cells. The
intracellular survival of Brucella is the most important factor in
its virulence and pathogenicity [17–19].
3.1. Antibacterial activity
An agar-well diffusion test showed the antibacterial activ-
ity of silver nanoparticles against B. melitensis 16M. The re-
sults showed that by increasing the concentration of silver
nanoparticles, the inhibition zone increases. The beginning of
the antibacterial effect was determined at a 10 ppm concentra-
tion of silver nanoparticles and at concentrations of more than
1000 ppm the increasing in antimicrobial effect was not signif-
icant (Figure 1).
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3.2. MIC and MBC
The results showed that the MIC and MBC of silver nanopar-
ticles for B. melitensis 16M was equal to 4 and 6 ppm, respec-
tively. Our findings indicated that the MIC and MBC of silver
nanoparticles for B. meliensis 16M was not toxic for murine
macrophages. Therefore, we used these concentrations of silver
nanoparticles to study the capability of silver nanoparticles in
killing intramacrophage B. melitesis 16M (high concentrations
of silver nanoparticles were found toxic for the macrophages
and were not used in macrophage culture).
3.3. Effect of incubation time
The incubation time is an important factor to assess the
antimicrobial ability of silver nanoparticles. This study showed
that silver nanoparticles were able to kill B. melitensis 16M
within 40 min. This finding indicated that silver nanoparticles
can be effective within a short time and may significantly
reduce the treatment time of brucellosis.
3.4. Effect of silver nanoparticles on macrophages
The viability of macrophages was investigated with several
dilutions of silver nanoparticles 24 h after incubation (Table 1).
The results indicated that concentrations of more than 6 ppm
have an inhibitory effect on peritoneal macorophages, while
this effect was not seen at lower concentrations. Therefore,
concentrations of less than 6 ppmwere used to study the effect
of silver nanoparticles on intramacrophages B. melitensis 16M.
3.5. Effect of silver nanoparticles on intramacrophages B. meliten-
sis 16M
The results showed a significant decrease in the number of
colonies formed in the test plates compared with the control
group (Table 2).
The results showed that silver nanoparticles have antimicro-
bial activity on intramacrophages B. melitensis 16M. The antimi-
crobial effect of silver nanoparticles on intramacrophages has
not been studied so far. It was found that concentrations of sil-
ver nanoparticles lower than 6 ppm have a significant effect on
elimination of intramacrophage B. melitensis 16M within 24 h.
Silver nanoparticles were found able to penetrate macrophage
cells and kill the bacteria. According to the results of this study
silver nanoparticles may be useful in the treatment of other
diseases caused by intracellular agents such as Salmonella and
should be checked in the future.Table 1: The means ± SD of viable macrophages at 24 h after treatment
with silver nanoparticles.
Silver nanoparticles
concentration (ppm)
% viable macrophages± SD after
24 h
12 63± 4*
10 70± 5*
8 85± 4*
6 89± 1
4 90± 5
2 93± 6
0 (negative control) 92± 4
* Indicates a significant difference compared with control group.
Table 2: The mean numbers of CFU of intramacrophages B. melitensis per
ml lysates by plating (primary inoculation was 5× 105 bacteria).
Silver nanoparticles concentration (ppm) Number of colonies± SD
6 No growth
4 28.8± 6
2 262.4± 24
1 587.6± 56
0 (negative control) 7360± 980
4. Conclusions
The results showed that silver nanoparticles have an antimi-
crobial effect against intramacrophage B. melitensis 16M and
that one may consider silver nanoparticles effective agents in
the treatment of brucellosis.
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